Drugs / PXS-5382A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04183517 | Dec 2019 → Apr 2020 | — | Syntara | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PXS-5382A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04183517 ↗ |
| Route | Oral | “Each subject during participation in the study will receive a dose of PXS 5382A orally in a fed state and a fasted state.” NCT04183517 ↗ |